{"nctId":"NCT02339246","briefTitle":"Pharmacokinetic Comparison Of All FK-506 Formulations","startDateStruct":{"date":"2015-01"},"conditions":["Renal Failure"],"count":32,"armGroups":[{"label":"Prograf vs Envarsus XR vs Astagraf XL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prograf vs Envarsus XR vs Astagraf XL"]},{"label":"Prograf vs Astagraf XL vs Envarsus XR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prograf vs Astagraf XL vs Envarsus XR"]}],"interventions":[{"name":"Prograf vs Envarsus XR vs Astagraf XL","otherNames":["Tacrolimus"]},{"name":"Prograf vs Astagraf XL vs Envarsus XR","otherNames":["Tacrolimus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Renal transplant recipients, males or females, of 18 years of age or above.\n2. Able to participate and willing to give written informed consent and to comply with study visits and restrictions.\n3. Able to understand English.\n4. Patients having received a primary or secondary renal transplant\n\nExclusion Criteria:\n\n1. Evidence of acute rejection episode within the past three months prior to screening.\n2. Recipients of organ transplants other than kidney.\n3. Patients who are known to be HIV positive.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.","description":"Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate T(max).\n\nNominal time points used were:\n\nPrograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24.\n\nEnvarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27.\n\nAstagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":null},{"groupId":"OG001","value":"1.93","spread":null},{"groupId":"OG002","value":"1.48","spread":null}]}]}]},{"type":"PRIMARY","title":"Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.","description":"Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate C(max).\n\nNominal time points used were:\n\nPrograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24.\n\nEnvarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27.\n\nAstagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.88","spread":"5.331"},{"groupId":"OG001","value":"13.17","spread":"12.49"},{"groupId":"OG002","value":"14.54","spread":"13.60"}]}]}]},{"type":"PRIMARY","title":"Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.","description":"Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate AUC(0-24).\n\nNominal time points used were:\n\nPrograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24.\n\nEnvarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27.\n\nAstagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213.41","spread":"83.095"},{"groupId":"OG001","value":"165.02","spread":"48.910"},{"groupId":"OG002","value":"176.52","spread":"50.799"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Diarrhea","Oedema peripheral","Headache","Vomiting","Fatigue"]}}}